CervoMed says UK grants ILAP Innovation Passport for neflamapimod in Lewy body dementia

Reuters2026/08/04 11:52

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

CervoMed’s neflamapimod received an Innovation Passport under the UK Innovative Licensing and Access Pathway for dementia with Lewy bodies.
The designation triggers coordinated regulatory and reimbursement engagement with MHRA, NHS, NICE, SMC, and AWTTC to support faster UK access.
CervoMed plans a Phase 3 trial for neflamapimod in dementia with Lewy bodies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-025509), on August 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

CervoMed says UK grants ILAP Innovation Passport for neflamapimod in Lewy body dementia

You may also like

Crypto prices